Discovery and evaluation of dual CDK1 and CDK2 inhibitors

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• Cyclin-dependent kinase (CDK) complexes are crucial regulators of the eukaryotic cell cycle.
• Cell cycle deregulation is a hallmark of cancer development.
• CDK1 and CDK2 are implicated in tumorigenesis and represent potential therapeutic targets.

Purpose of the Study:

• To validate cyclin-dependent kinase 1 (CDK1) and cyclin-dependent kinase 2 (CDK2) as therapeutic targets in cancer.
• To evaluate novel selective small-molecule inhibitors (CDKi) targeting cyclin B1/CDK1 and cyclin E2/CDK2 enzyme complexes.
• To assess the efficacy of these CDKi in preclinical cancer models.

Main Methods:

• Development of flow cytometry assays to measure intracellular retinoblastoma (Rb) phosphorylation as a marker of CDK pathway inhibition.
• Treatment of various tumor cell lines with selective CDK1 and CDK2 inhibitors.
• In vitro and in vivo studies using established cancer cell lines and xenograft models (colon, prostate, breast).

Main Results:

• CDK inhibitors significantly decreased tumor cell proliferation and induced G1/G2 cell cycle arrest and apoptosis in a cell line-specific manner.
• Inhibition of CDK pathway was confirmed by reduced Rb phosphorylation.
• Tumor growth was suppressed in vivo, with inhibitors preventing tumor progression in colon and prostate cancer models.
• Cell cycle arrest occurred independently of p53 status, even in p53-deficient tumor cells.

Conclusions:

• Novel potent and selective inhibitors of CDK1 and CDK2 are effective in reducing cancer cell proliferation and tumor growth.
• These findings validate CDK1 and CDK2 as promising therapeutic targets for cancer treatment.
• The p53-independent mechanism of action suggests broad applicability of these inhibitors across different tumor types.